Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Liver fibrosis
Ramón Bataller, David A. Brenner
Ramón Bataller, David A. Brenner
Published February 1, 2005
Citation Information: J Clin Invest. 2005;115(2):209-218. https://doi.org/10.1172/JCI24282.
View: Text | PDF | Corrigendum
Science in Medicine Article has an altmetric score of 213

Liver fibrosis

  • Text
  • PDF
Abstract

Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Our knowledge of the cellular and molecular mechanisms of liver fibrosis has greatly advanced. Activated hepatic stellate cells, portal fibroblasts, and myofibroblasts of bone marrow origin have been identified as major collagen-producing cells in the injured liver. These cells are activated by fibrogenic cytokines such as TGF-β1, angiotensin II, and leptin. Reversibility of advanced liver fibrosis in patients has been recently documented, which has stimulated researchers to develop antifibrotic drugs. Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins. Although many therapeutic interventions are effective in experimental models of liver fibrosis, their efficacy and safety in humans is unknown. This review summarizes recent progress in the study of the pathogenesis and diagnosis of liver fibrosis and discusses current antifibrotic strategies.

Authors

Ramón Bataller, David A. Brenner

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 Total
Citations: 67 147 153 179 178 149 133 138 131 150 152 119 102 102 88 73 53 44 27 22 2 2209
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2006 (22)

Title and authors Publication Year
Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia
R Khan, R Sheppard
Immunology 2006
Pancreas recovery following cerulein-induced pancreatitis is impaired in plasminogen-deficient mice
A Lugea, L Nan, SW French, JA Bezerra, AS Gukovskaya, SJ Pandol
Gastroenterology 2006
CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells
LM McAllister-Lucas, J Ruland, K Siu, X Jin, S Gu, DS Kim, P Kuffa, D Kohrt, TW Mak, G Nuñez, PC Lucas
Proceedings of the National Academy of Sciences 2006
Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein
P Sanz-Cameno, S Martín-Vílchez, E Lara-Pezzi, MJ Borque, J Salmerón, PM de Rueda, JA Solís, M López-Cabrera, R Moreno-Otero
The American Journal of Pathology 2006
Involvement of PPAR nuclear receptors in tissue injury and wound repair
L Michalik, W Wahli
Journal of Clinical Investigation 2006
Resistin as an Intrahepatic Cytokine
C Bertolani, P Sancho-Bru, P Failli, R Bataller, S Aleffi, R DeFranco, B Mazzinghi, P Romagnani, S Milani, P Ginés, J Colmenero, M Parola, S Gelmini, R Tarquini, G Laffi, M Pinzani, F Marra
The American Journal of Pathology 2006
Galectin-3 regulates myofibroblast activation and hepatic fibrosis
NC Henderson, AC Mackinnon, SL Farnworth, F Poirier, FP Russo, JP Iredale, C Haslett, KJ Simpson, T Sethi
Proceedings of the National Academy of Sciences 2006
Molecular therapy for hepatic injury and fibrosis: Where are we?
Prosser CC, Yen RD, Wu J
World journal of gastroenterology : WJG 2006
A Role for Serotonin (5-HT) in Hepatic Stellate Cell Function and Liver Fibrosis
RG Ruddell, F Oakley, Z Hussain, I Yeung, LJ Bryan-Lluka, GA Ramm, DA Mann
The American Journal of Pathology 2006
Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans
E Novo, F Marra, E Zamara, LV di Bonzo, L Monitillo, S Cannito, I Petrai, A Mazzocca, A Bonacchi, RS de Franco, S Colombatto, R Autelli, M Pinzani, M Parola
Gut 2006
Human hepatic stellate cells are resistant to apoptosis: implications for human fibrogenic liver disease
N Kawada
Gut 2006
Effect of Chinese medicine Qinggan Huoxuefang on inducing HSC apoptosis in alcoholic liver fibrosis rats
G Ji, L Wang, SH Zhang, JW Liu, PY Zheng, T Liu
World journal of gastroenterology : WJG 2006
Filtrate of fermented mycelia from Antrodia camphorata reduces liver fibrosis induced by carbon tetrachloride in rats
Lin WC, Kuo SC, Lin WL, Fang HL, Wang BC
World journal of gastroenterology : WJG 2006
Assessment of liver fibrosis by a noninvasive method of transient elastography and biochemical markers
Kawamoto M, Mizuguchi T, Katsuramaki T, Nagayama M, Oshima H, Kawasaki H, Nobuoka T, Kimura Y, Hirata K
World journal of gastroenterology : WJG 2006
Gene expression profiling defined pathways correlated with fibroblast cell proliferation induced by Opisthorchis viverrini excretory/secretory product
Thuwajit C, Thuwajit P, Uchida K, Daorueang D, Kaewkes S, Wongkham S, Miwa M
World journal of gastroenterology : WJG 2006
Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-β1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C
Janczewska-Kazek E, Marek B, Kajdaniuk D, Borgiel-Marek H
World journal of gastroenterology : WJG 2006
GFAP promoter directs lacZ expression specifically in a rat hepatic stellate cell line
Maubach G, Lim MC, Zhang CY, Zhuo L
World journal of gastroenterology : WJG 2006
Analysis of gene expression changes in relation to toxicity and tumorigenesis in the livers of Big Blue transgenic rats fed comfrey (Symphytum officinale).
Mei N, Guo L, Zhang L, Shi L, Sun YA, Fung C, Moland CL, Dial SL, Fuscoe JC, Chen T
BMC bioinformatics 2006
Morphological characterisation of portal myofibroblasts and hepatic stellate cells in the normal dog liver.
Ijzer J, Roskams T, Molenbeek RF, Ultee T, Penning LC, Rothuizen J, van den Ingh TS
Comparative hepatology 2006
PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells.
Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM
Biochemical and Biophysical Research Communications 2006
Thiazolidinediones and hepatic fibrosis: don't wait too long.
Marra F
Gut 2006
The vignette for V13N3 issue
Lai MM
Journal of biomedical science 2006

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 20 news outlets
Blogged by 5
Referenced in 1 policy sources
Posted by 7 X users
Referenced in 31 patents
On 2 Facebook pages
Referenced in 1 Wikipedia pages
Referenced in 2 clinical guideline sources
1396 readers on Mendeley
6 readers on CiteULike
See more details